Diane Weiser | executive |
Robert I. Blum | executive |
Fady Malik | executive |
Stuart Kupfer | executive |
Andrew Callos | executive |
Robert Wong | executive |
Ching Jaw | executive |
Joseph Pantginis | analyst |
Dane Leone | analyst |
Salim Syed | analyst |
Serge Belanger | analyst |
Fatima Amanat | analyst |
Jason Butler | analyst |
Srikripa Devarakonda | analyst |
Hannah Latimer | analyst |
Yasmeen Rahimi | analyst |
Charles Duncan | analyst |
Roanna Clarissa Ruiz | analyst |
Justin Kim | analyst |
Good afternoon, and welcome, ladies and gentlemen, to Cytokinetics Third Quarter 2023 Conference Call. At this time, I would like to inform you that this call is being recorded.[Operator Instructions] I would now turn the call over to Diane Weiser, Cytokinetics Senior Vice President of Corporate Communications and Investor Relations. Please go ahead.
Good afternoon, and thanks for joining us on the call today. Robert Blum, President and Chief Executive Officer, will begin with an overview of the quarter and recent developments.